Ocugen, Inc. - 8-K Filing

Ocugen enters exclusive license agreement with Celairis Therapeutics for OCU400 commercialization in Australia, New Zealand, and ASEAN markets. (Items: 7.01 and Exhibit 99, 9.01 Financial Statements and Exhibits)

2 articles from 2 sources · updated November 10, 2026, 16:06 UTC

Coverage

• Ocugen Outlicenses Gene Therapy Candidate OCU400 to Celairis Therapeutics for Asia-Pacific Region Seeking Alpha · November 10, 2026, 16:02 UTC
• Ocugen, Inc. - 8-K Filing SEC EDGAR · November 10, 2026, 13:30 UTC